The first and only FDA-approved intravenous immunoglobulin with two maintenance dosing options for CIDP Pfizer Inc. today announced that the U.S. Food and Drug Administration has approved the supplemental Biologics License Application for PANZYGA ® to treat adult patients with a rare neurological disease of the peripheral nerves called chronic inflammatory demyelinating polyneuropathy . PANZYGA is the only ...